Mody et al. indicated that rosiglitazone inhibited the viability and DNA synthesis of breast cancer cells, which in turn enhanced the sensitivity of tumor cells to tumor necrosis factor alpha (TNFα) and ultimately induced cell apoptosis. This evidence concerns the gene TNF and breast carcinoma.